Redox-Assisted Protein Folding Systems in Eukaryotic Parasites

Saikh Jaharul Haque^{1,2} Tanmay Majumdar,^{3,4} and Sailen Barik^{3,4}

Abstract

Significance: The cysteine (Cys) residues of proteins play two fundamentally important roles. They serve as sites of post-translational redox modifications as well as influence the conformation of the protein through the formation of disulfide bonds. **Recent Advances:** Redox-related and redox-associated protein folding in protozoan parasites has been found to be a major mode of regulation, affecting myriad aspects of the parasitic life cycle, host-parasite interactions, and the disease pathology. Available genome sequences of various parasites have begun to complement the classical biochemical and enzymological studies of these processes. In this article, we summarize the reversible Cys disulfide (S-S) bond formation in various classes of strategically important parasitic proteins, and its structural consequence and functional relevance. **Critical Issues:** Molecular mechanisms of folding remain under-studied and often disconnected from functional relevance. **Future Directions:** The clinical benefit of redox research will require a comprehensive characterization of the various isoforms and paralogs of the redox enzymes and their concerted effect on the structure and function of the specific parasitic client proteins. *Antioxid. Redox Signal.* 17, 674–683.

Introduction

A LARGE VARIETY of unicellular and multicellular parasites infect human and other animals, causing wide-ranging diseases. Notable unicellular parasites include *Plasmodium*, *Toxoplasma*, *Trypanosoma*, *Leishmania*, *Trichomonas*, *Giardia*, and *Entamoeba*, whereas the multicellular parasites include *Schistosoma*, *Filariidae*, *Echinococcus*, *Onchocerca*, and *Trichuris*. All parasites are global health problems, but are particularly endemic in tropical and subtropical regions. Malaria, caused by *Plasmodia*, alone claims the lives of about two million people every year, many in sub-Saharan Africa (59). Toxoplasmosis is also common globally transmitted through ingestion of raw or under-cooked meat as well as via domestic cats (53). Nearly a third of the U.S. population is estimated to be *Toxoplasma*-positive by immunological criteria. Toxoplasmosis is especially hazardous in pregnancy, often leading to miscarriage or babies born with blindness and encephalitis. *Leishmania* causes leishmaniasis that ranges from skin rashes to fever and systemic infections, even death (69). Approximately half-a-million people in 36 sub-Saharan African nations suffer from African trypanosomiasis, commonly known as “sleeping sickness”, caused by *Trypanosoma brucei* and transmitted by the tsetse fly (62). The other human form

of trypanosomiasis, called Chagas disease, is caused by *T. cruzi* and causes roughly 20,000 deaths per year, mainly in Latin America. *Giardia* and *Entamoeba* cause severe enteric diseases (4). Schistosomiasis, sometimes called snail fever, is caused by several species of *Schistosoma*, commonly recognized as platyhelminths or flukes (79). Although it has a low mortality rate, chronic schistosomiasis affects 200 million people worldwide and damages internal organs. It is the second most socioeconomically devastating parasitic disease after malaria.

In part due to the eukaryotic nature of the parasites, antibacterial and antiviral drugs are ineffective against them. To minimize the toxicity of the anti-parasitic drugs to the higher eukaryotic hosts, the logical approach is to capitalize on parasite-specific proteins and pathways that are absent in or significantly different from the host. In this article, we review and examine parasitic-specific Cys modifications that are essential for protein folding and, hence, may serve as potential drug targets.

Directed by their amino-acid sequences, nascent polypeptide chains form short secondary structures, such as α helices and β strands, often flanked by flexible loops, which are subsequently folded into stable three-dimensional structures. The inability of a polypeptide chain to fold into its native higher order

¹Department of Pathobiology and ²Pulmonary and Critical Care Medicine and Brain Tumor Institute, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio.

³Center for Gene Regulation in Health and Disease and ⁴Department of Biological, Geological and Environmental Sciences, College of Sciences and Health Professions, Cleveland State University, Cleveland, Ohio.

conformation impairs its functions and increases its degradation (38, 55). Although the primary structure of a polypeptide largely governs its folding potential into a native tertiary structure, other factors, including van der Waals interactions, chaperons, hydrogen bonding, and disulfide bonding, also play critical roles in the folding process (19, 22, 39).

Two Cys residues residing in different parts of a polypeptide chain or in two different polypeptide chains but are adjacent in the tertiary or quaternary structure can be oxidized to form a disulfide (S-S) bond (22, 55) (Fig. 1). This electron transfer reaction requires an oxidative micro-environment, which, in eukaryotes, is provided by the lumen of the endoplasmic reticulum (ER) (45, 80, 81). Small-molecule oxidants, such as glutathione, cysteamine disulfides, dehydroascorbate and vitamin K epoxide as well as redox enzymes, such as protein disulfide isomerase (PDI) and sulfhydryloxidase, serve as electron acceptors in disulfide bond formation. In this Forum Review article, we focus on a few specialized parasitic enzymes that affect or catalyze disulfide reactions, while other articles in this series cover the rest.

Protein Disulfide Isomerases

A resident of the ER, PDI is a multi-domain multifunctional enzyme that belongs to the thioredoxin (Trx) superfamily and catalyzes the reversible formation of disulfide bonds between Cys residues within proteins (74, 76), which are often rate-limiting steps in protein folding, thus accelerating the correct folding of their client proteins (21–23). The prototype PDI contains the domain structure *a-b-b'-a'*; whereas the *a* and *a'* domains show sequence similarity to Trx and contain two Cys-X-X-Cys (CXXC) active sites; the *b*, *b'* domains are redox inactive and show structural similarity to Trx without significant sequence homology (27, 34).

FIG. 1. Schematic of redox reactions. (A) Representative thiol-disulfide exchange reaction between a protein and an electron acceptor reagent. This two-step reaction between the redox reagent ($R_1-S-S-R_2$) and a substrate protein leads to a disulfide bond formation in the protein and reduction of the electron acceptor. (B) Flow of reducing equivalents through the structural domains of a metazoan Quiescin-sulfhydryl oxidase during catalysis. The thioredoxin (Trx), Helix-rich region (HRR) and the Erv/ALR domains, and the six Cys residues (C^I–C^{VI}) have been described in the text. (To see this illustration in color, the reader is referred to the web version of this article at www.liebertonline.com/ars). Cys, cysteine.

In general, unfolded proteins are not only functionally suboptimal or fully useless but also activate ER stress via the unfolded protein response, which can be detrimental to cell survival (36). Disulfide bond formation during protein folding is mediated by two thiol-disulfide exchange reactions (21, 23, 38). In the first step, a reactive thiolate anion (S[−]) in the reduced form of a protein displaces one sulfur atom from an oxidized (disulfide-bonded) redox reagent, resulting in the formation of a mixed disulfide bond between the protein and the redox reagent. In the second step, the remaining thiol anion attacks the mixed disulfide bond, leading to the formation of the oxidized protein (Fig. 1A) (21, 23, 38). Disulfide bond formation is also mediated by a process called disulfide reshuffling in which cysteine thiolate anion of a protein attacks an existing disulfide bond on the same protein to generate a new disulfide bond.

PDI itself undergoes reversible Cys disulfide formation, such that its reduced (dithiol) form catalyzes reduction of mispaired thiol residues of the substrate and acts as an isomerase. PDI, therefore, essentially promotes the post-translational modification by disulfide exchange. It is to be noted that in prokaryotes, the Dsb family enzymes catalyze the same reaction and reside in the periplasmic space, through which proteins traffic to their extracytoplasmic destinations (49, 65, 76). Moreover, in eukaryotes, the flavin adenine dinucleotide (FAD)-linked sulfhydryl oxidase, Erv1, which resides in the intermembrane mitochondrial space and forms a redox cycle with Mia40 through a disulfide relay, plays an essential role in the maturation of cytoplasmic proteins through the formation of disulfide bonds (18, 23, 29, 32, 77). The major additional task of PDI is to function as a chaperone, that is, assist misfolded proteins to attain a correctly folded state without enzymatic disulfide shuffling. Studies in yeast have revealed the essentiality of PDI for cell survival (31, 66).

In a leading study (54), nine PDI-like sequences were noted in five species of malaria parasites, including *Plasmodium falciparum* and *Plasmodium vivax* (both human), *Plasmodium knowlesi* (monkey), and *Plasmodium berghei* and *Plasmodium yoelii* (both mouse). PlasmoDB identifies four PDI-like sequences in the *P. falciparum* genome that are located on four chromosomes 8, 9, 11, and 14, and named accordingly: PfPDI-8, PfPDI-9, PfPDI-11, and PfPDI-14 (Fig. 2). Significant sequence similarity of plasmodial PDI with the PDI of other species together with the experimental demonstration of PDI activity of a number of recombinant PfPDI (see below) suggest that all PDI sequences in the parasite may be functional. All four PfPDIs have cleavable N-terminal signal peptides, one or two thioredoxin reductase (TR) domains, and a C-terminal ER-retention signal (such as SEEL in PfPDI-8), suggesting that all locate to ER (Fig. 2). Only PfPDI-8 seems to conform to the classical PDI structure *a-b-b'-a'*, consisting of two Trx domains, each with a pair of active Cys sites as a part of the Cys-Gly-His-Cys (CGHC) active site motif. PfPDI-9, 11, and 14, in contrast, have only one Trx domain with the active site motif Cys-Lys-Glu-Cys (CKEC) and CGHC, respectively, closely resembling the *a'* (C-terminal) domain of other organisms (Fig. 2). In another variation, the single Trx domain of PfPDI-11 aligns with the *a* (N-terminal) domain (54).

PfPDI-8 was expressed and biochemically characterized in two laboratories (54, 63). The protein exhibited typical biochemical functions of a PDI: oxidase/isomerase and reductase activities, as well as a chaperone-like behavior on a

FIG. 2. Schematic of the major domains of plasmodial PDI enzymes. Pf=*Plasmodium falciparum*, Pb=*Plasmodium berghei*, Pk=*Plasmodium knowlesi*, Pv=*Plasmodium vivax*, Py=*Plasmodium yoelii*. The suffix numbers (e.g., PfPDI-8) refer to the number of the known chromosomes in which the protein disulfide isomerase gene is located. The GenBank accession numbers are, from the top, NP_704277, NP_704733, NP_701212, NP_702583, DQ266891, DQ266890, DQ266892, and EAA17481. The number of amino-acid residues in each polypeptide is shown on the right. The boxed domains with their catalytic CXXC motif are color-coded. The *a-b-b'-a'* arrangement of the domains are also highlighted in color, whereby *a* and *a'* are the N- and C-terminal catalytic domains, and *b*, *b'* are catalytically inactive. We refrained from applying the letter designation to PfPDI-11 due to the relatively central position of its single CGHS domain and the lack of knowledge of its catalytic activity. The N-terminal signal peptide (Blue) and C-terminal ER retention sequences (tetrapeptides) are indicated. The drawing scale is approximate. (To see this illustration in color, the reader is referred to the web version of this article at www.liebertonline.com/ars). CXXC, Cys-X-X-Cys; CGHS, Cys-Gly-His-Cys; ER, endoplasmic reticulum; PDI, protein disulfide isomerase.

denatured protein substrate. The protein was found in the parasitic ER and is absent in the Golgi. The antiplasmodial compound DS61 inhibited the recombinant PfPDI oxidase/isomerase activity but not that of the human recombinant PDI, pointing to structural differences between the two and suggesting that PfPDI is a potential target for novel antimalarials that may be structurally related to DS61.

Multiplicity of PDI homologs is not unique to *P. falciparum* but is rather common in all organisms; yeast, for example, has at least 6 (33), and humans have 14 (28). This is most likely because each PDI enzyme has unique, nonredundant functions related to their substrate specificity, cellular location, regulation, and association with specific accessory proteins, thus allowing their involvement in different pathways. Lastly, multiple PDI sequences of various domain structures, including the PfPDI-8 prototype (Fig. 2), are also found in other protozoan parasites (54), notably *Toxoplasma*, *Cryptosporidium*, *Giardia* (58), *Trypanosoma* (73), and *Leishmania* (68). Based on what we know about PDI in *Plasmodium*, the PDI of these

parasites are also likely to be essential for infection and, hence, useful as potential drug targets.

A large number of exported parasite proteins, essential for virulence and pathogenesis, transit through the ER for proper folding (54, 63). They also contain multiple Cys residues at conserved positions within well-defined protein domains, disulfide linkages of which are essential for functionality. Such domains include the F2-domain of EBA-175 (82, 86), epidermal growth factor (EGF)-like domains of merozoite surface protein-1 (MSP-1) (41), the ectodomain of apical merozoite antigen-1 (AMA-1) (7, 26, 44), and host-cell-receptor binding (cytoadherence) domains of the erythrocyte membrane protein 1 (PfEMP1) (11, 59). All these proteins are likely substrates for one or more PfPDI.

Next, we describe three of these—AMA-1, EMP1, and MSP-1—in some detail.

The best studied of these is the AMA-1 protein, which requires eight intramolecular disulfide bonds to attain its final conformation and is essential for the erythrocyte invasion (44). The crystal structures of three AMA-1 proteins from different *Plasmodium* species, namely *P. falciparum*, *P. chabaudi*, and *P. vivax* have been determined so far (9, 44, 70). The AMA1 proteins in all *Plasmodia* contain 16 invariant Cys residues in the ectoplasmic region, and analysis of the disulfide-bond pattern suggests a division into three distinct domains (9, 44, 57, 64, 70), containing three, two, and three disulfide bridges, respectively (Fig. 3). Correct disulfide pairing in the recombinant AMA-1 protein is indeed essential for protective immune response (7), which underscores the need for redox-assisted folding for AMA1-based vaccine development.

PfEMP1 is responsible for a phenomenon named “rosetting”, in which *P. falciparum* causes infected red blood cells (RBC) to form rosettes with uninfected RBC, which is characteristic of severe malaria (15, 72). The protein is exported to the erythrocyte surface via ER (2, 85) and requires correct folding of its Cys-rich interdomain region (CIDR) for cytoadhesiveness. PfEMP1 contains the following major domains (Fig. 4): N-terminal segment (NTS), Duffy binding-like (DBL), and CIDR (48). The α -class DBL1, which follows NTS, has been directly implicated in rosette formation, and forms multiple Cys-Cys bridges (pair of oxidized Cys joined by disulfide bridge [S-S]) (Fig. 4), which change the structure of the NTS-DBL α module (48).

Finally, the *P. falciparum* MSP-1 contains two closely packed EGF-like domains, each stabilized by three disulfide bonds. The structure of this domain, as determined for *P. falciparum* and *P. knowlesi*, (37, 47, 60), revealed all six disulfide bonds that are required for correct folding of the dual domain protein (Fig. 5). These studies are highly relevant, partly because MSP-1 is a leading vaccine candidate and its native conformation is important for invasion (41).

Quiescin-Sulfhydryl Oxidase

Sulfhydryl oxidases (also see Ero1 below) are believed to be required for the generation of disulfide bonds in a variety of organisms (38). The Quiescin-sulfhydryl oxidase (QSOX) family of flavoenzymes (42, 50) catalyzes the direct and facile insertion of disulfide bonds into unfolded or denatured proteins with concomitant reduction of oxygen to hydrogen peroxide (H_2O_2). The reaction can be summarized as follows: $2R-SH + O_2 \rightarrow R-S-S-R + H_2O_2$ (Fig. 1A). In contrast to other

FIG. 3. A schematic representation of eight Cys pairs of PfAMA-1 bridged by disulfide bonds. The Cys residues (C with numbers) and the S-S bridges are indicated in red. The three domains are shown as I, II, and III (9, 44, 64, 70). Note that the disulfide bridges generate proper folding of the protein. (To see this illustration in color, the reader is referred to the web version of this article at www.liebertonline.com/ars).

flavoprotein sulfhydryl oxidases, QSOX directly oxidizes a wide range of reduced proteins and peptides without mediation of PDI or small molecules.

The QSOX members are FAD-linked enzymes expressed in a wide variety of eukaryotic organisms except in fungi and yeast (50). A prototype QSOX is comprised of four domains: two Trx domains (Trx1 and Trx2), followed by a helix-rich region of unknown functions and the C-terminal Erv/ALR domain that serves as the oxidative catalytic engine that forms an FAD-mediated connection between and thiol/disulfide and molecular oxygen (18, 21, 22, 39). Interestingly, QSOX enzymes of protozoan parasites (see below), green algae, and higher plants lack the Trx2 domain partially or completely (19, 22, 39). Four potential redox-active groups—one FAD and three CXXC disulfide motifs—are found in QSOX proteins (55). The solvent exposed C^I in the Trx1 domain forms a mixed disulfide bond first with the donor substrate and then with C^{III} of the proximal CXXC in the Erv/ALR domain. On reduction, the C^{IV} thiol interacts with and reduces the oxidized flavin through charge transfer, and the catalytic cycle is completed with the divalent reduction of molecular oxygen to H₂O₂ (Fig. 1B) (55). Collectively, the Trx1 and Trx2 domains are similar to the *a* and *b* domains of the PDI, mentioned earlier. QSOX sequences are found in a number of unicellular parasites, including *P. falciparum*, *Cryptosporidium parvum*,

Trypanosoma brucei, and *Leishmania major*. Recently, the single QSOX homolog of *T. brucei* was recombinantly expressed and studied in detail (51). Although evidently lacking an entire domain, TbQSOX showed catalytic activity and substrate specificity similar to the vertebrate QSOXs. Unfolded reduced proteins were more than 200-fold more effective substrates on a per-thiol basis than glutathione, and about 10-fold better than the parasite bis-glutathione analog, trypanothione. These results were considered consistent with a role for TbQSOX in oxidative protein folding. Site-directed mutagenesis of each of the six Cys residues (to Ser) showed that the CXXC motif in the single Trx domain is crucial for efficient catalysis of oxidation. It was also confirmed that the proximal disulfide C^{III}–C^{IV}, which interacts with the flavin, was catalytically crucial. Overall, in spite of its single Trx domain, TbQSOX showed a striking enzymatic similarity to its double-Trx metazoan counterparts.

Ero1 Class of Sulfhydryl Oxidase

Very similar to QSOX, the Ero1 family members are also flavin-dependent sulfhydryl oxidases, found in a number of parasites. Unlike QSOX, the Ero1 family is found in yeast and higher eukaryotes (49). Both families lack an obvious ER retention signal, but it is possible that they may be retained in

FIG. 4. Schematic diagram of the PfEMP1 polypeptide. The relevant domains are shown in grayscale codes and detailed in the text. The seven key Cys residues of the DBL1 α domain involved in disulfide bridge formation are indicated in the expanded view. (To see this illustration in color, the reader is referred to the web version of this article at www.liebertonline.com/ars).

the ER lumen by association with a PDI homolog, where Ero1 can promote re-oxidation of the reduced PDI (67, 75, 84, 46). Both *T. brucei* and *P. falciparum* contain a single homolog of Ero1 (54), and sequence alignment revealed that similar to human Ero1 α , this molecule has 15 cysteine residues with two conserved Cys triads that are critical for Ero1 α function, suggesting that malaria thiol-oxidation pathway utilizes a mechanism that is similar to other eukaryotes. However, neither protein has been biochemically characterized. *Giardia lamblia* genome, while encoding five PDI homologs, lacks Ero1 (58, 61).

Cyclophilin A of *Schistosoma*: Folding Regulated by Intramolecular Disulfide

Helminths are multicellular eukaryotic parasites that infect over one-fourth of the world population and are believed to induce type 2 T cell immunity, leading to atopic diseases, such as allergy and asthma (56). As mentioned earlier, *Schistosoma* is a major helminth that causes schistosomiasis and human morbidity in tropical countries (5). Since the extracellular parasite is exposed to reactive oxygen species derived from the host immune cells as well as from its own oxygen metabolism, *Schistosoma* has developed an efficient antioxidant defense mechanism comprising thioredoxin peroxidase-1 (Tpx-1), Trx, and thioredoxin reductase (TrxR) (5, 52). Since this organism lacks catalase and expresses low levels of glutathione peroxidase, it utilizes Tpx-1 for the detoxification of H₂O₂ and other hydroperoxides (5). Importantly, the Trx/TrxR system also provides reducing equivalents to disulfide-mediated protein folding in this organism (8). The immune suppressant, cyclosporin A (CsA), which targets cyclophilins (CyPs) (see below), is widely used for the treatment of schistosomiasis (5).

The CyP family represents ubiquitous chaperones that help a large cohort of client proteins to fold properly (1, 10). Their inherent PPIase activity and biological function are pharmacologically inhibited by CsA, a cyclic undecapeptide, first isolated from the fungus *Tolypocladium inflatum* by Sandoz researchers in Norway nearly half a century ago (13). Classic crystallographic studies revealed that CsA functions by tightly binding the PPIase catalytic pocket (83). However, it remains largely unknown whether the structure or function of CyP itself is regulated. A recent study of Cyclophilin A of *Schistosoma mansoni* (SmCyPA) revealed an interesting mechanism of regulation. SmCyPA uniquely contains two closely spaced Cys residues, namely Cys122 and Cys126; although the first Cys is conserved in other CyPs, the second is not, and is often replaced by a Thr. The juxtaposition of

Cys122 and Cys126 allows reversible disulfide bond formation between the two and the resultant formation of an oxidized or a reduced state of SmCyPA, a phenomenon not reported for any other CyP. Parallel functional studies suggested a mechanism for regulation of SmCyPA activity via oxidation of its thiol groups, such that oxidized SmCyPA was inactive, whereas reduced SmCyPA was found to be an efficient isomerase, inhibited by low nanomolar CsA. The mechanism of this dramatic difference in catalytic activity was revealed when high-resolution X-ray crystal structures were

FIG. 5. Crystal structure of PfMSP-1, showing the S-S bridged Cys pairs. The structure is based on the solution NMR structure of PfMSP-1 (NCBI 1CEJ) (47). The beta-strands are yellow, and the loops are green. The six Cys (C) disulfide pairs are C7-C18, C12-C28, C30-C41, C49-C62, C56-C76, and C78-C92. The pairs are shown in a stick model colored by their location in the secondary structure. (To see this illustration in color, the reader is referred to the web version of this article at www.liebertonline.com/ars). This and all other structures in this article were drawn by PyMOL (24).

obtained for both the oxidized and the reduced forms (40). The Cys122 and Cys126 were found to be located in the vicinity of the active site and at a distance of 3.8 Å from each other. Formation of disulfide bridge between the two resulted in significant alteration of three major structural pockets lined by functionally important residues. To illustrate, we present representative superimposed structures of the two forms (Fig. 6). Comparison of the ribbon presentations (Fig. 6A) shows that there was little or no change in the overall protein backbone due to the disulfide bridge. However, when the amino-acid side chains were compared, those of key amino acids were found to be shifted. Such residues included not only the catalytic residue Arg62 (Fig. 6A), but also many others such as Glu100, Arg98, and Asp127 (Fig. 6B). Thus, SmCyPA is a unique chaperone whose own folding and enzymatic activity is reversibly regulated by an intramolecular disulfide bridge, which is, in turn, regulated by the redox environment of the parasitic cytoplasm. Lastly, the confidence gained from these structural studies may allow the development of alternative and more effective schistosomiasis inhibitors targeting the dual Cys-thiol region of SmCyPA, as it is absent in all human CyPs.

Cys Disulfide-Assisted Folding of Trypanosome Variable Surface Glycoproteins

A major role of redox-assisted folding in unicellular parasites is exemplified by the variable surface glycoproteins (VSGs) of trypanosomes. Many parasites, such as *Trypanosoma* and *Plasmodia*, have evolved a common mechanism to evade host immune response and maintain a low level of chronic infection in their natural hosts (20). This is achieved through antigenic variation of the VSGs that constitute the coat proteins of the parasite. As implied, the coat is highly immunogenic and elicits a robust antibody response. However, the parasite genome contains roughly a thousand VSG genes that are constantly switched on and off, such that the VSG makeup of the coat keeps changing, allowing evasion of host immunity and perpetuation of infection.

An average VSG polypeptide is a little more than 400 amino acids long and consists of a single large N-terminal domain of 350–400 residues and one or two smaller C-terminal domains (6, 14, 16). Interestingly, in addition to being heavily glycosylated, each domain contains a string of conserved Cys residues, many of which are disulfide bonded in a characteristic pattern, even though the overall sequence, especially that of the N-terminal domain, is highly variable. A representative example (Fig. 7) shows two Cys disulfide bridges in the Type A VSGs. The experimentally determined three-dimensional structure of the same proteins (12, 17, 35) revealed the close proximity of the bridging Cys residues (Fig. 8). The overall importance of Cys in the structural integrity of VSG was tested by site-directed mutagenesis of selected C-terminal Cys residues to Ala. The $^1\text{H-NMR}$ spectra of the purified recombinant mutants showed considerably less dispersion of resonances, indicating that no mutant retained the structure of wild-type VSG.

The exact redox system responsible for VSG disulfide formation is yet to be identified. Nonetheless, *Trypanosoma* are known to have an unusual redox biology, in which a bis-glutathione derivative, trypanothione, plays a major role (30). As mentioned here and in other articles in this Forum, three

FIG. 6. Cys disulfide formation causes rotation of amino-acid side chains. In *Schistosoma* cyclophilin A (CyPA), the two closely spaced Cys residues, Cys122 and Cys126, undergo reversible oxidation reduction. This does not appreciably change the secondary structural elements of the protein, as shown by the perfect superimposition of the two structures, with NCBI PDB ID 2CK1 (oxidized) and 2CMT (reduced) (Panel A). However, a number of amino-acid side chains shifted positions, which includes the active site residue Arg62 (yellow in the oxidized, pink in the reduced structure). A few other rotated side chains are also illustrated in contrasting colors (Panel B). (To see this illustration in color, the reader is referred to the web version of this article at www.liebertonline.com/ars).

flavin-linked sulfhydryl oxidases can be identified in the *T. brucei* genome, namely TbALR, Ero1, and the QSOX described earlier. Of these, the last two are found in the ER, and, thus, likely to participate in disulfide-promoted folding of the VSGs that traffic through ER for glycosylation as well.

FIG. 7. Two representative Cys pairs in the corresponding positions of two Tb VSG primary structures. The VSG names are shown on the left. Horizontal brackets indicate the two S-S bridges in blue (Cys15-Cys145) and red (Cys123-Cys187), respectively (6, 14). The corresponding crystal structures are shown in Figure 8. (To see this illustration in color, the reader is referred to the web version of this article at www.liebertonline.com/ars). VSG, variable surface glycoprotein.

Secreted Redox Chaperones and Their Extracellular Immune Roles

Accumulating literature has provided evidence for an intriguingly novel role of chaperones as a potential extracellular entity. Many molecular chaperones, including those involved in redox-assisted protein folding, are secreted from cells and function as signals for a variety of cells, such as the macrophages (43). The major extracellular chaperones involved in parasite infection are Trx and peroxiredoxin, as briefly described next.

The Trx superfamily consists of redox enzymes that contain the CXXC motif and catalyze oxidative protein folding through disulfide formation. The prototype full-length Trx is a

roughly 100 amino acid-long polypeptide of ~12 kDa, whereas a naturally truncated form of Trx is known that contains only 80–84 N-terminal residues and, hence, is named Trx80. The latter is produced and released by monocytes, and was originally discovered as an eosinophil cytotoxicity-enhancing factor in the blood of patients with schistosomiasis (78). The exact mechanism of the generation and function of Trx80 and the role of the parasite in these processes, if any, remain to be elucidated. However, Trx and Trx reductases are now known in a number of platyhelminth parasites, such as *S. mansoni*, *Echinococcus granulosus*, and *Taenia crassiceps* (3, 5, 71), all of which cause chronic immune pathologies. It would be interesting to find out whether similar Trx-related products also serve as extracellular immune regulators in these parasite infections.

Peroxiredoxin was, in fact, initially known as macrophage 23-kDa stress protein and has been found to be an essential intracellular inhibitor of macrophage activation by lipopolysaccharide (LPS) (87). In chronic parasitic infections, macrophages are activated and are associated with a polarized Th2 response. This could be replicated in a laboratory mouse model of latent as well as chronic infection by the liver fluke, *Fasciola hepatica*, a trematode. *F. hepatica* is the causative agent of fasciolosis, a zoonosis that affects cattle and causes major losses in agriculture and dairy. The alternative activation state of macrophages was induced by both live flukes and parasite excretory–secretory products, the active component of which was found to be peroxiredoxin. In a direct experiment, purified recombinant *F. hepatica* peroxiredoxin alternatively activated mouse macrophage cells as evidenced by the production of interleukin (IL)-10, prostaglandin E2, and correspondingly low IL-12 levels (25).

FIG. 8. X-ray diffraction crystal structures of two representative Tb VSG. Ribbon diagram of the crystal structures shows the similar locations of a set of bridged Cys pairs in the two higher order structures even though the primary structures were substantially dissimilar due to the need for antigenic variability in the VSG proteins (12, 17, 35). These and other Cys-Cys disulfide bridges (pair of oxidized Cys joined by disulfide bridge [S-S]) play a crucial role in imparting the native conformation to VSG. The PDB numbers of the two structures (at NCBI) are 1VSG (MITat1.2) and 2VSG (ILTat 1.24). A line drawing of the same two polypeptides is shown in Figure 7. (To see this illustration in color, the reader is referred to the web version of this article at www.liebertonline.com/ars).

Conclusion

Reversible Cys disulfide bridges clearly regulate the structure and function of a large variety of proteins in protozoan and metazoan parasites. There is now a growing body of evidence that these proteins play essential roles in not only parasite growth but also host-parasite signaling and immune response. The parasitic enzymes that catalyze the thiol redox reaction possess conserved as well as unique domains, making them lucrative targets for new drug development. Nonetheless, various aspects of regulation and function of these enzymes are still unknown and will certainly constitute major research areas of the future.

Acknowledgments

This work was supported in part by a grant from the Michael J. Fox Foundation for Parkinson's Research (SB), a State of Ohio Third Frontier grant (SB), and U.S. National Institutes of Health (NIH) grants 1R43 GM090383 (SB) and R56 AI083638 (SJH). The authors wish to thank DeLano Scientific for making the PyMol program freely available.

References

- Adams B, Musiyenko A, Kumar R, and Barik S. A novel class of dual-family immunophilins. *J Biol Chem* 280: 24308–24314, 2005.
- Adisa A, Rug M, Foley M, and Tilley L. Characterisation of a delta-COP homologue in the malaria parasite, *Plasmodium falciparum*. *Mol Biochem Parasitol* 123: 11–21, 2002.
- Agorio A, Chalar C, Cardozo S, and Salinas G. Alternative mRNAs arising from trans-splicing code for mitochondrial and cytosolic variants of *Echinococcus granulosus* thioredoxin glutathione reductase. *J Biol Chem* 278: 12920–12928, 2003.
- Aguilar-Díaz H, Carrero JC, Argüello-García R, Laclette JP, and Morales-Montor J. Cyst and encystment in protozoan parasites: optimal targets for new life-cycle interrupting strategies? *Trends Parasitol* 27: 450–458, 2011.
- Alger HM and Williams DL. The disulfide redox system of *Schistosoma mansoni* and the importance of a multifunctional enzyme, thioredoxin glutathione reductase. *Mol Biochem Parasitol* 121: 129–139, 2002.
- Allen G and Gurnett LP. Locations of the six disulfide bonds in a variant surface glycoprotein (VSG 117) from *Trypanosoma brucei*. *Biochem J* 209: 481–487, 1983.
- Anders RF, Crewther PE, Edwards S, Margetts M, Matthew ML, Pollock B, and Pye D. Immunisation with recombinant AMA-1 protects mice against infection with *Plasmodium chabaudi*. *Vaccine* 16: 240–247, 1998.
- Arner ES and Holmgren A. Physiological functions of thioredoxin and thioredoxin reductase. *Eur J Biochem* 267: 6102–6109, 2000.
- Bai T, Becker M, Gupta A, Strike P, Murphy VJ, Anders RF, and Batchelor AH. Structure of AMA1 from *Plasmodium falciparum* reveals a clustering of polymorphisms that surround a conserved hydrophobic pocket. *Proc Natl Acad Sci USA* 102: 12736–12741, 2005.
- Barik S. Immunophilins: for the love of proteins. *Cell Mol Life Sci* 63: 2889–2900, 2006.
- Baruch DI, Gamain B, Barnwell JW, Sullivan JS, Stowers A, Galland GG, Miller LH, and Collins WE. Immunization of Aotus monkeys with a functional domain of the *Plasmodium falciparum* variant antigen induces protection against a lethal parasite line. *Proc Natl Acad Sci USA* 99: 3860–3865, 2002.
- Blum ML, Down JA, Gurnett AM, Carrington M, Turner MJ, and Wiley DC. A structural motif in the variant surface glycoproteins of *Trypanosoma brucei*. *Nature* 362: 603–609, 1993.
- Borel JF. History of the discovery of cyclosporin and of its early pharmacological development. *Wien Klin Wochenschr* 114: 433–437, 2002.
- Bussler H, Linder M, Linder D, and Reinwald E. Determination of the disulfide bonds within a B domain variant surface glycoprotein from *Trypanosoma congolense*. *J Biol Chem* 273: 32582–32586, 1998.
- Carlson J, Helmby H, Hill AV, Brewster D, Greenwood BM, and Wahlgren M. Human cerebral malaria: association with erythrocyte resetting and lack of anti-rosetting antibodies. *Lancet* 336: 1457–1460, 1990.
- Carrington M, Miller N, Blum M, Roditi I, Wiley D, and Turner M. Variant specific glycoprotein of *Trypanosoma brucei* consists of two domains each having an independently conserved pattern of cysteine residues. *J Mol Biol* 221: 823–835, 1991.
- Chattopadhyay A, Jones NG, Nietlispach D, Nielsen PR, Voorheis HP, Mott HR, and Carrington M. Structure of the C-terminal domain from *Trypanosoma brucei* variant surface glycoprotein MITat1.2. *J Biol Chem* 280: 7228–7235, 2005.
- Coppock DL and Thorpe C. Multidomain flavin-dependent sulfhydryl oxidases. *Antioxid Redox Signal* 8: 300–311, 2006.
- Creighton TE, Darby NJ, and Kemmink J. The roles of partly folded intermediates in protein folding. *FASEB J* 10: 110–118, 1996.
- Cross GAM. Antigenic variation in trypanosomes - secrets surface slowly. *Bioessays* 18: 283–291, 1996.
- Darby N and Creighton TE. Disulfide bonds in protein folding and stability. *Methods Mol Biol* 40: 219–252, 1995.
- Darby NJ, Penka E, and Vincentelli R. The multi-domain structure of protein disulfide isomerase is essential for high catalytic efficiency. *J Mol Biol* 276: 239–247, 1998.
- Depuydt M, Messens J, and Collet JF. How proteins form disulfide bonds. *Antioxid Redox Signal* 15: 49–66, 2011.
- DeLano WL. The PyMOL Molecular Graphics System. 2002. DeLano Scientific, San Carlos, CA, USA. www.pymol.org. (accessed November 1, 2011).
- Donnelly S, O'Neill SM, Sekiya M, Mulcahy G, and Dalton JP. Thioredoxin peroxidase secreted by *Fasciola hepatica* induces the alternative activation of macrophages. *Infect Immun* 73: 166–173, 2005.
- Dutta S, Lalitha PV, Ware LA, Barbosa A, Moch JK, Vassell MA, Fileta BB, Kitov S, Kolodny N, Heppner DG, Haynes JD, and Lanar DE. Purification, characterization, and immunogenicity of the refolded ectodomain of the *Plasmodium falciparum* apical membrane antigen 1 expressed in *Escherichia coli*. *Infect Immun* 70: 3101–3110, 2002.
- Edman JC, Ellis L, Blacher RW, Roth RA, and Rutter WJ. Sequence of protein disulphide isomerase and implications of its relationship to thioredoxin. *Nature* 317: 267–270, 1985.
- Ellgaard L and Ruddock LW. The human protein disulphide isomerase family: substrate interactions and functional properties. *EMBO Rep* 6: 28–32, 2005.
- Endo T, Yamano K, and Kawano S. Structural basis for the disulfide relay system in the mitochondrial intermembrane space. *Antioxid Redox Signal* 13: 1359–1373, 2010.
- Fairlamb AH, Blackburn P, Ulrich P, Chait BT, and Cerami A. Trypanothione: a novel bis(glutathionyl) spermidine cofactor for glutathione reductase in trypanosomatids. *Science* 227: 1485–1487, 1985.
- Farquhar R, Honey N, Murrant SJ, Bossier P, Schultz L, Montgomery D, Ellis RW, Freedman RB, and Tuite MF.

- Protein disulfide isomerase is essential for viability in *Saccharomyces cerevisiae*. *Gene* 108: 81–89, 1991.
32. Fass D. The Erv family of sulfhydryl oxidases. *Biochim Biophys Acta* 1783: 557–566, 2008.
 33. Frand AR, Cuozzo JW, and Kaiser CA. Pathways for protein disulphide bond formation. *Trends Cell Biol* 10: 203–210, 2000.
 34. Freedman RB, Hirst TR, and Tuite MF. Protein disulphide isomerase: building bridges in protein folding. *Trends Biochem Sci* 19: 331–336, 1994.
 35. Freymann D, Down J, Carrington M, Roditi I, Turner M, and Wiley D. 2.9 Å resolution structure of the N-terminal domain of a variant surface glycoprotein from *Trypanosoma brucei*. *J Mol Biol* 216: 141–160, 1990.
 36. Gardner BM and Walter P. Unfolded proteins are Ire1-activating ligands that directly induce the unfolded protein response. *Science* 333: 1891–1894, 2011.
 37. Garman SC, Simcoke WN, Stowers AW, and Garboczi DN. Structure of the C-terminal domains of merozoite surface protein-1 from *Plasmodium knowlesi* reveals a novel histidine binding site. *J Biol Chem* 278: 7264–7269, 2003.
 38. Goldberg AL. Protein degradation and protection against misfolded or damaged proteins. *Nature* 426: 895–899, 2003.
 39. Goldenberg DP and Creighton TE. Energetics of protein-structure and folding. *Biopolymers* 24: 167–182, 1985.
 40. Gourlay LJ, Angelucci F, Baiocco P, Boumis G, Brunori M, Bellelli A, and Miele AE. The three-dimensional structure of two redox states of cyclophilin A from *Schistosoma mansoni*. Evidence for redox regulation of peptidyl-prolyl cis-trans isomerase activity. *J Biol Chem* 282: 24851–24857, 2007.
 41. Guevara Patiño JA, Holder AA, McBride JS, and Blackman MJ. Antibodies that inhibit malaria merozoite surface protein-1 processing and erythrocyte invasion are blocked by naturally acquired human antibodies. *J Exp Med* 186: 1689–1699, 1997.
 42. Heckler EJ, Rancy PC, Kodali VK, and Thorpe C. Generating disulfides with the Quiescin-sulfhydryl oxidases. *Biochim Biophys Acta* 1783: 567–77, 2008.
 43. Henderson B and Henderson S. Unfolding the relationship between secreted molecular chaperones and macrophage activation states. *Cell Stress Chaperones* 14: 329–341, 2009.
 44. Hodder AN, Crewther PE, Matthew ML, Reid GE, Moritz RL, Simpson RJ, and Anders RF. The disulfide bond structure of *Plasmodium* apical membrane antigen-1. *J Biol Chem* 271: 29446–29452, 1996.
 45. Hooper KL and Thorpe C. Flavin-dependent sulfhydryl oxidases in protein disulfide bond formation. *Methods Enzymol* 348: 30–34, 2002.
 46. Inaba K, Masui S, Iida H, Vavassori S, Sitia R, and Suzuki M. Crystal structures of human Ero1 α reveal the mechanisms of regulated and targeted oxidation of PDI. *EMBO J* 29: 3330–3343, 2010.
 47. James S, Moehle K, Renard A, Mueller MS, Vogel D, Zurbriggen R, Pluschke G, and Robinson JA. Synthesis, solution structure and immune recognition of an epidermal growth factor-like domain from *Plasmodium falciparum* merozoite surface protein-1. *ChemBiochem* 7: 1943–1950, 2006.
 48. Juillerat A, Lewit-Bentley A, Guillotte M, Gangnard S, Hessel A, Baron B, Vigan-Womas I, England P, Mercereau-Puijalon O, and Bentley GA. Structure of a *Plasmodium falciparum* PfEMP1 rosetting domain reveals a role for the N-terminal segment in heparin-mediated rosette inhibition. *Proc Natl Acad Sci USA* 108: 5243–5248, 2011.
 49. Kadokura, H. Oxidative protein folding: many different ways to introduce disulfide bonds. *Antioxid Redox Signal* 8: 731–733, 2006.
 50. Kodali VK and Thorpe C. Oxidative protein folding and the Quiescin-sulfhydryl oxidase family of flavoproteins. *Antioxid Redox Signal* 13: 1217–1230, 2010.
 51. Kodali VK and Thorpe C. Quiescin sulfhydryl oxidase from *Trypanosoma brucei*: catalytic activity and mechanism of a QSOX family member with a single thioredoxin domain. *Biochemistry* 49: 2075–2085, 2010.
 52. Kwatia MA, Botkin DJ, and Williams DL. Molecular and enzymatic characterization of *Schistosoma mansoni* thioredoxin peroxidase. *J Parasitol* 86: 908–915, 2000.
 53. Lindsay DS and Dubey JP. Toxoplasma gondii: the changing paradigm of congenital toxoplasmosis. *Parasitology* 9: 1–3, 2011.
 54. Mahajan B, Noiva R, Yadava A, Zheng H, Majam V, Mohan KV, Moch JK, Haynes JD, Nakhasi H, and Kumar S. Protein disulfide isomerase assisted protein folding in malaria parasites. *Int J Parasitol* 36: 1037–1048, 2006.
 55. Mainathambika BS and Bardwell JC. Disulfide-linked protein folding pathways. *Annu Rev Cell Dev Biol* 24: 211–235, 2008.
 56. Maizels RM, Pearce EJ, Artis D, Yazdanbakhsh M, and Wynn TA. Regulation of pathogenesis and immunity in helminth infections. *J Exp Med* 206: 2059–2066, 2009.
 57. Marshall VM, Peterson MG, Lew AM, and Kemp DJ. Structure of the apical membrane antigen I (AMA-1) of *Plasmodium chabaudi*. *Mol Biochem Parasitol* 37: 281–283, 1989.
 58. McArthur AG, Knodler LA, Silberman JD, Davids BJ, Gillin FD, and Sogin ML. The evolutionary origins of eukaryotic protein disulfide isomerase domains: new evidence from the Amitochondriate protist *Giardia lamblia*. *Mol Biol Evol* 18: 1455–1463, 2001.
 59. Miller LH, Baruch DI, Marsh K, and Doumbo OK. The pathogenic basis of malaria. *Nature* 415: 673–679, 2002.
 60. Morgan WD, Birdsall B, Frenkiel TA, Gradwell MG, Burghaus PA, Syed SE, Uthaipibull C, Holder AA, and Feeney J. Solution structure of an EGF module pair from the *Plasmodium falciparum* merozoite surface protein 1. *J Mol Biol* 289: 113–122, 1999.
 61. Morrison HG, McArthur AG, Gillin FD, Aley SB, Adam RD, Olsen GJ, Best AA, Cande WZ, Chen F, Cipriano MJ, Davids BJ, Dawson SC, Elmendorf HG, Hehl AB, Holder ME, Huse SM, Kim UU, Lasek-Nesselquist E, Manning G, Nigam A, Nixon JE, Palm D, Passamaneck NE, Prabhu A, Reich CI, Reiner DS, Samuelson J, Svard SG, and Sogin ML. Genomic minimalism in the early diverging intestinal parasite *Giardia lamblia*. *Science* 317: 1921–1926, 2007.
 62. Morrison LJ. Parasite-driven pathogenesis in *Trypanosoma brucei* infections. *Parasite Immunol* 33: 448–455, 2011.
 63. Mouray E, Moutiez M, Girault S, Sergheraert C, Florent I, and Grellier P. Biochemical properties and cellular localization of *Plasmodium falciparum* protein disulfide isomerase. *Biochimie* 89: 337–346, 2007.
 64. Nair M, Hinds MG, Coley AM, Hodder AN, Foley M, Anders RF, and Norton RS. Structure of domain III of the blood-stage malaria vaccine candidate, *Plasmodium falciparum* apical membrane antigen 1 (AMA1). *J Mol Biol* 322: 741–753, 2002.
 65. Nakamoto H and Bardwell JC. Catalysis of disulfide bond formation and isomerization in the *Escherichia coli* periplasm. *Biochim Biophys Acta* 1694: 111–119, 2004.
 66. Norgaard P, Westphal V, Tachibana C, Alsoe L, Holst B, and Winther JR. Functional differences in yeast protein disulfide isomerases. *J Cell Biol* 152: 553–562, 2001.
 67. Otsu M, Bertoli G, Fagioli C, Guerini-Rocco E, Nerini-Molteni S, Ruffato E, and Sitia R. Dynamic retention of

- Ero1alpha and Ero1beta in the endoplasmic reticulum by interactions with PDI and ERp44. *Antioxid Redox Signal* 8: 274–282, 2006.
68. Padilla A, Noiva R, Lee N, Mohan KV, Nakhasi HL, and Debrabant A. An atypical protein disulfide isomerase from the protozoan parasite *Leishmania* containing a single thioredoxin-like domain. *J Biol Chem* 278: 1872–1878, 2003.
 69. Palatnik-de-Sousa CB and Day MJ. One Health: the global challenge of epidemic and endemic leishmaniasis. *Parasit Vectors* 4:197, 2011.
 70. Pizarro JC, Vulliez-Le Normand B, Chesne-Seck ML, Collins CR, Withers-Martinez C, Hackett F, Blackman MJ, Faber BW, Remarque EJ, Kocken CH, Thomas AW, and Bentley GA. Crystal structure of the malaria vaccine candidate apical membrane antigen 1. *Science* 308: 408–411, 2005.
 71. Rendon JL, Del AI, Guevara-Flores A, Uribe A, Plancarte A, and Mendoza-Hernandez G. Purification, characterization and kinetic properties of the multifunctional thioredoxin-glutathione reductase from *Taenia crassiceps* metacystode (cysticerci). *Mol Biochem Parasitol* 133: 61–69, 2004.
 72. Rowe JA, Moulds JM, Newbold CI, and Miller LH. P. falciparum rosetting mediated by a parasite-variant erythrocyte membrane protein and complement-receptor 1. *Nature* 388:292–295, 1997.
 73. Rubotham J, Woods K, Garcia-Salcedo JA, Pays E, and Nolan DP. Characterization of two protein disulfide isomerases from the endocytic pathway of bloodstream forms of *Trypanosoma brucei*. *J Biol Chem* 280: 10410–10418, 2005.
 74. Sevier CS and Kaiser CA. Conservation and diversity of the cellular disulfide bond formation pathways. *Antioxid Redox Sign* 8: 797–811, 2006.
 75. Sevier CS and Kaiser CA. Ero1 and redox homeostasis in the endoplasmic reticulum. *Biochim Biophys Acta* 1783: 549–556, 2008.
 76. Sevier CS and Kaiser CA. Formation and transfer of disulfide bonds in living cells. *Nat Rev Mol Cell Biol* 3: 836–847, 2002.
 77. Sideris DP and Tokatlidis K. Oxidative protein folding in the mitochondrial intermembrane space. *Antioxid Redox Signal* 13: 1189–1204, 2010.
 78. Silberstein DS, Ali MH, Baker SL, and David JR. Human eosinophil cytotoxicity-enhancing factor. Purification, physical characteristics, and partial amino acid sequence of an active polypeptide. *J Immunol* 143: 979–983, 1989.
 79. Swain MT, Larkin DM, Caffrey CR, Davies SJ, Loukas A, Skelly PJ, and Hoffmann KF. Schistosoma comparative genomics: integrating genome structure, parasite biology and anthelmintic discovery. *Trends Parasitol* 27: 555–564, 2011.
 80. Thorpe C and Coppock DL. Generating disulfides in multicellular organisms: emerging roles for a new flavoprotein family. *J Biol Chem* 282: 13929–13933, 2007.
 81. Thorpe C, Hooper KL, Raje S, Glynn NM, Burnside J, Turi GK, and Coppock DL. Sulfhydryl oxidases: emerging catalysts of protein disulfide bond formation in eukaryotes. *Arch Biochem Biophys* 405: 1–12, 2002.
 82. Tolia NH, Enemark EJ, Sim BK, and Joshua-Tor L. Structural basis for the EBA-175 erythrocyte invasion pathway of the malaria parasite *Plasmodium falciparum*. *Cell* 122: 183–193, 2005.
 83. Venugopal V, Datta AK, Bhattacharyya D, Dasgupta D, and Banerjee R. Structure of cyclophilin from *Leishmania donovani* bound to cyclosporin at 2.6 Å resolution: correlation between structure and thermodynamic data. *Acta Crystallogr D Biol Crystallogr* 65: 1187–1195, 2009.
 84. Vitu E, Kim S, Sevier CS, Lutzky O, Heldman N, Bentzur M, Unger T, Yonda M, Kaiser CA, and Fass D. Oxidative activity of yeast Ero1p on protein disulfide isomerase and related oxidoreductases of the endoplasmic reticulum. *J Biol Chem* 285: 18155–18165, 2010.
 85. Wickham ME, Rug M, Ralph SA, Klonis N, McFadden GI, Tilley L, and Cowman AF. Trafficking and assembly of the cytoadherence complex in *Plasmodium falciparum*-infected human erythrocytes. *EMBO J* 20: 5636–5649, 2001.
 86. Yadava A and Ockenhouse CF. Effect of codon optimization on expression levels of a functionally folded malaria vaccine candidate in prokaryotic and eukaryotic expression systems. *Infect Immun* 71: 4961–4969, 2003.
 87. Yang CS, Lee DS, Song CH, An SJ, Li S, Kim JM, Kim CS, Yoo DG, Jeon BH, Yang HY, Lee TH, Lee ZW, El-Benna J, Yu DY, and Jo EK. Roles of peroxiredoxin II in the regulation of proinflammatory responses to LPS and protection against endotoxin-induced lethal shock. *J Exp Med* 204: 583–594, 2007.

Address correspondence to:

Dr. Sailen Barik

Department of Biological, Geological and Environmental Sciences

College of Sciences and Health Professions

Cleveland State University

2121 Euclid Ave.

Cleveland, OH 44115

E-mail: s.barik@csuohio.edu

Date of first submission to ARS Central, November 24, 2011;

date of acceptance, November 28, 2011.

Abbreviations Used

AMA-1 = apical merozoite antigen-1
 CGHC = Cys-Gly-His-Cys
 CIDR = Cys-rich interdomain region
 CsA = cyclosporin A
 CyP = cyclophilin
 Cys = cysteine
 Cys-Cys = pair of oxidized Cys joined by disulfide bridge (S-S)
 CXXC = Cys-X-X-Cys
 DBL = Duffy binding-like
 EGF = epidermal growth factor
 ER = endoplasmic reticulum
 FAD = flavin adenine dinucleotide
 H₂O₂ = hydrogen peroxide
 HRR = Helix-rich region
 IL = interleukin
 MSP-1 = merozoite surface protein-1
 NTS = N-terminal segment
 PDI = protein disulfide isomerase
 PfEMP1 = erythrocyte membrane protein 1
 QSOX = Quiescin-sulfhydryl oxidase
 RBC = red blood cells
 SmCyPA = Cyclophilin A of *Schistosoma mansoni*
 Tpx = thioredoxin peroxidase
 Trx = thioredoxin
 TrxR = thioredoxin reductase
 VSG = variable surface glycoprotein.